Janux Therapeutics, Inc. Common Stock

JANX · Pharmaceutical Preparations · $1.0B
Falling back
JANX
$16.59
▼ −1.60%
09/18 O 16.70 H 16.86 L 16.40 C 16.59 ▼ −1.60%
Vol 2.4M RS 41
RS rating41
Now vs pivot (%)−1.86%
Tightening (ATR ratio)0.98×
Volume dry-up1.38×
Up/down volume, net0.11
From 52-week high53%
failed pokeplayed out
Previous breakout stopped out ▼ −9.96% in Jul
Falling back
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 5.6 weeks and fell 14% from its ceiling at its deepest. The pivot is $16.91, and the stock closed 1.9% below it. Its relative strength rating is 41.

Peers
Catalyst roadmap
  1. EarningstentativeLLY · competitorin 41d
    LLY reports
    Oct 29, 2026
  2. Earningstentativein 48d
    Quarterly earnings
    Nov 5, 2026
Flagged by the market sweep
GappedTape · 2026-09-16
-5.0%
GappedTape · 2026-09-11
-8.5%

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.

In the news
4 Prostate Cancer Drug Stocks to Watch During Awareness MonthZacks Investment Research · 4 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Janux Therapeutics, Inc. Common Stock (JANX) — The Tape